Overview

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Status:
Terminated

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

Taiho Oncology, Inc.